Physician

Shahabul Arfeen, M.D.

According to 2025 Medicare claims, Shahabul Arfeen, M.D. (NPI: 1538164140) practices nephrology in the Michigan City-La Porte, IN market, with the plurality of this provider's patient population coming from La Porte, IN. This provider's primary affiliated billing organization is NEPHROLOGY SPECIALISTS, PC. (NPI: 1881671865; TIN: 351601196) and primary practice location at 46360-4358.

Arfeen's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 371 traditional Medicare patients, billed 1,702 HCPCS/CPT codes, and received $143,483 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 1,681 prescription claims across 224 beneficiaries totaling $289,370 in drug costs, led by Ozempic (Semaglutide). DME data shows 17 claims. Open Payments data shows 17 records totaling $433. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $310,508 to $143,483. Similarly, Part D prescription costs have moved from a higher plateau to a lower plateau, from $504,318 to $289,370. In contrast, DME billing represents a smaller volume and rose steadily, from $941 to $2,599.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	525	3,308	$310,508
2016	516	3,920	$353,646
2017	544	4,083	$339,932
2018	472	3,162	$277,946
2019	562	3,492	$310,565
2020	512	2,820	$272,186
2021	465	2,468	$240,025
2022	438	2,129	$191,287
2023	418	2,187	$195,122
2024	371	1,702	$143,483

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	224	3,172	$504,318
2016	255	2,961	$470,617
2017	280	2,816	$421,057
2018	248	2,402	$236,491
2019	255	2,061	$170,628
2020	226	1,599	$166,421
2021	235	1,655	$200,520
2022	222	1,537	$199,046
2023	219	1,684	$333,462
2024	224	1,681	$289,370

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	177	$11,062
2016	N/R	285	$12,748
2017	N/R	270	$11,354
2018	N/R	242	$10,473
2019	N/R	185	$6,377
2020	N/R	103	$3,583
2021	N/R	125	$4,624
2022	N/R	173	$6,144
2023	N/R	72	$2,930
2024	N/R	17	$263

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	137	188	$115
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	107	311	$79
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	169	545	$52
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	153	323	$44
93050	Analysis of central arterial pressure with review by physician	50	58	$10

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ozempic	Semaglutide	42	2,162	$55,017
Farxiga	Dapagliflozin Propanediol	58	2,760	$50,612
Trulicity	Dulaglutide	30	1,150	$38,715
Rybelsus	Semaglutide	24	1,140	$35,960
Jardiance	Empagliflozin	22	1,130	$22,685

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	17	$263

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	17	$433	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Shahabul Arfeen, M.D.?

Tedicare shows public-source Medicare data for Shahabul Arfeen, M.D. (NPI 1538164140), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Shahabul Arfeen, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Shahabul Arfeen, M.D.?

Shahabul Arfeen, M.D. is linked to NEPHROLOGY SPECIALISTS, PC. (billing NPI 1881671865) in the available physician profile data.

Does Shahabul Arfeen, M.D. have Open Payments data?

Shahabul Arfeen, M.D. has 17 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.